• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Qualigen Therapeutics Inc.

    11/12/25 5:17:50 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QLGN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    QUALIGEN THERAPEUTICS, INC.

    (Name of Issuer)


    COMMON STOCK, $0.001 PAR VALUE PER SHARE

    (Title of Class of Securities)


    74754R301

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    74754R301


    1Names of Reporting Persons

    Alpha Capital Anstalt
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    LIECHTENSTEIN
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    153,545.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    153,545.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    153,545.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.056 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  Note to 5, 7, 9 and 11: Based on 1,695,450 shares outstanding as of September 22, 2025 as reported on DEF-14A filed with the Securities and Exchange Commission on October 20, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    QUALIGEN THERAPEUTICS, INC.
    (b)Address of issuer's principal executive offices:

    2042 Corte Del Nogal, Carlsbad, California 92011
    Item 2. 
    (a)Name of person filing:

    Alpha Capital Anstalt
    (b)Address or principal business office or, if none, residence:

    Altenbach 8, FL-9490 Vaduz, Liechtenstein
    (c)Citizenship:

    Liechtenstein
    (d)Title of class of securities:

    COMMON STOCK, $0.001 PAR VALUE PER SHARE
    (e)CUSIP No.:

    74754R301
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    153,545.00
    (b)Percent of class:

    9.056%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    153,545.00

     (ii) Shared power to vote or to direct the vote:

    0 Shares

     (iii) Sole power to dispose or to direct the disposition of:

    153,545.00

     (iv) Shared power to dispose or to direct the disposition of:

    0 Shares

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Alpha Capital Anstalt
     
    Signature:/s/ Konrad Ackermann
    Name/Title:Konrad Ackermann/Director
    Date:11/12/2025
    Get the next $QLGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QLGN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QLGN
    SEC Filings

    View All

    SEC Form 8-K filed by Qualigen Therapeutics Inc.

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    11/21/25 4:30:27 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qualigen Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    11/21/25 4:23:28 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Qualigen Therapeutics Inc.

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    11/20/25 5:10:25 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QLGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Qualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 Strategy

    Shareholders approved all proposals, confirming Faraday Future Intelligent Electric Inc. ("Faraday Future") as the Company's new majority and controlling shareholder.Faraday Future will nominate a majority of board seats prior to November 20 as part of the Company's strategic transformation.The Company will host an official renaming and ticker activation ceremony at Nasdaq Headquarters in New York on November 20, adopting the new ticker symbol AIXC.During the ceremony, the Company will unveil a new business model, ecosystem structure, and three-year development roadmap positioning AIxCrypto as a leading gateway to the AI × Web3 era.The transition introduces cross-ecosystem enablement between

    11/16/25 4:10:00 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025

    Dubai, UAE / Beijing, China, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics Inc. (NASDAQ:QLGN) ("Qualigen", "QLGN" or the "Company"), a publicly-traded technology company majority owned by Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) ("Faraday Future" or "FF"), today announced that it will rebrand as AIxCrypto following its stockholder meeting on November 12, 2025. AIxCrypto's Strategic Roadmap QLGN (soon to be AIxCrypto) has launched its new Web3 and crypto asset business initiatives. Following its targeted rebranding on November 12, the Company will launch the public beta of its BesTrade DeAI Agent by the end of November and release its EAI RWA Utility Token Whitepap

    10/27/25 11:57:00 PM ET
    $FFAI
    $QLGN
    Auto Manufacturing
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation

    New York, NY, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics Inc. (NASDAQ:QLGN) ("Qualigen", "QLGN" or "Company"), a publicly-trading technology company majority owned by Faraday Future, today announced a strategic partnership with BitGo, the digital asset infrastructure company, to support its C10 treasury strategy, which accumulate and compound a market-cap-weighted basket of the world's top 10 crypto assets (excluding stablecoins). Through this partnership, Qualigen will leverage BitGo's holistic treasury management offering1 that combines access to deep liquidity with secure qualified custody. BitGo's OTC desk will enable Qualigen to efficiently invest across a diversified ba

    10/23/25 4:05:00 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QLGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Bensler Graydon

    3 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)

    11/15/24 4:05:33 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Braeden Lichti

    3 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)

    10/17/24 4:05:15 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Lim Robert Bradley

    3 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)

    8/9/24 4:01:09 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QLGN
    Financials

    Live finance-specific insights

    View All

    Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023

    Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack® diagnostics business for approximately $5 million in all cash transaction to support advancement of therapeutics pipeline CARLSBAD, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces financial results for the second quarter ending June 30, 2023, and provides a corporate update: Highlights For Second Quarter and To Date 2023: Therapeutics Highlights: QN-

    8/15/23 8:30:00 AM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023

    Company Reports 123% Increase in Year-Over-Year Revenue CARLSBAD, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces financial results for the first quarter ending March 31, 2023, and provides a corporate update. Highlights For First Quarter and To Date 2023: Therapeutics Highlights: QN-302 Orphan Drug Designation granted by FDA for the intended indication of pancreatic cancerGood laboratory practice (GLP) toxicology studies initiatedComposition

    5/16/23 8:00:00 AM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

    CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN, Inc.))), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces financial results for the fourth quarter and fiscal year ended December 31, 2022, and provides an update on the company's therapeutics pipeline and other corporate developments. Highlights For 2022 and to Date: Therapeutics Highlights: QN-302 Secured worldwide rights to G4-selective transcription inhibitors from University College London to develop as cancer therapeuticsEngaged QN

    5/2/23 4:30:00 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QLGN
    Leadership Updates

    Live Leadership Updates

    View All

    Qualigen Therapeutics, Inc. Announces management changes.

    CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors of the Company (the Board") of his intention to resign as chief executive officer and Chairman of the Board of the Company, effective immediately. On the same date, Mr. Christopher Lotz, Chief Financial Office also tendered his resignation from the company, effective immediately. Both resignations were attributed to disagreements with the Company regarding its future direction and strategic initiatives. On September 25, 2024, the board of directors appointed Campbell Becher as President of the

    9/26/24 5:10:00 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice President

    CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, announces today that it has appointed Shishir Sinha, the Company's newly promoted Senior Vice President and current Chief Operating Officer, to lead the Company's diagnostics division. "Shishir's consistent leadership as chief operating officer has been an essential part of our strategy to date. With the return of the sales and marketing of FastPack® last month, our diagnostics business is an essential asset to t

    4/29/22 9:15:00 AM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qualigen Therapeutics, Inc. Appoints Tariq Arshad, MD, MBA as Chief Medical Officer

    New Position Created to Deepen Clinical Expertise and Advance Pipeline Therapeutic Programs CARLSBAD, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, today announced the appointment of Tariq Arshad, MD, MBA to the newly-created position of Senior Vice President, Chief Medical Officer. Dr. Arshad brings more than 20 years of biotech and pharmaceutical experience to Qualigen Therapeutics during a dynamic time of growth and implementation of long-range strategy. "We are delighted to welcome Tariq to Qualigen as our Chief Medical Off

    5/19/21 7:30:00 AM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QLGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Qualigen Therapeutics Inc. (Amendment)

    SC 13G/A - Qualigen Therapeutics, Inc. (0001460702) (Subject)

    5/27/22 9:22:10 AM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Qualigen Therapeutics, Inc.

    SC 13G - Qualigen Therapeutics, Inc. (0001460702) (Subject)

    12/6/21 5:04:28 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care